Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EU Agrees to Buy Potential Sanofi, GSK Covid-19 Vaccine

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:25am EDT

By Mauro Orru

The European Commission said Friday that it has signed a contract with Sanofi SA and GlaxoSmithKline PLC to secure up to 300 million doses of their potential Covid-19 vaccine.

The commission, the EU's executive arm, didn't disclose financial details but said the contract marks the second deal the EU has struck for the supply of vaccines against coronavirus, following a deal it already signed with British drug maker AstraZeneca PLC.

"Agreements with other companies will be concluded soon and build a diversified portfolio of promising vaccines, based on various types of technologies, increasing our chances to find an effective remedy against the virus," European Commission President Ursula von der Leyen said.

Sanofi and GSK aim to have the vaccine available by the second half of 2021, after starting a Phase 1 and 2 study in September, with a Phase 3 study by the end of 2020.

 

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

 


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.14% 8123 Delayed Quote.6.60%
GLAXOSMITHKLINE PLC -0.82% 1398.4 Delayed Quote.-21.50%
SANOFI -0.69% 85.44 Real-time Quote.-4.66%
share with twitter share with LinkedIn share with facebook
All news about SANOFI
12:50pFrance's Ose to enrol up to 400 for 'T-cell' coronavirus vaccine trials
RE
12:50pFrance's Ose to enroll up to 400 for 'T-cell' coronavirus vaccine trials
RE
10:22aREGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Children Ag..
AQ
10:22aSANOFI : - CHMP recommends approval of Dupixent for children aged 6 to 11 years ..
AQ
03:41aSANOFI : Gets a Buy rating from Goldman Sachs
MD
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
RE
10/16SANOFI : and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody..
AQ
10/16REGENERON PHARMACEUTICALS : Sanofi Get CHMP Backing for Dupixent in Children Wit..
DJ
10/16SANOFI : CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 t..
AQ
10/16SANOFI : CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 t..
AQ
More news
Financials
Sales 2020 36 532 M 42 991 M 42 991 M
Net income 2020 11 441 M 13 464 M 13 464 M
Net Debt 2020 7 901 M 9 298 M 9 298 M
P/E ratio 2020 9,48x
Yield 2020 3,73%
Capitalization 107 B 126 B 126 B
EV / Sales 2020 3,15x
EV / Sales 2021 2,95x
Nbr of Employees 100 409
Free-Float 89,0%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105,24 €
Last Close Price 85,44 €
Spread / Highest target 43,8%
Spread / Average Target 23,2%
Spread / Lowest Target -0,51%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.01%126 624
JOHNSON & JOHNSON1.53%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-14.09%190 074